Cytokinetics, Incorporated
CYTK
$60.07
$0.070.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.76M | 1.94M | 66.77M | 1.58M | 16.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.76M | 1.94M | 66.77M | 1.58M | 16.93M |
| Cost of Revenue | 104.40M | 99.23M | 112.55M | 99.84M | 93.63M |
| Gross Profit | -86.64M | -97.30M | -45.79M | -98.26M | -76.70M |
| SG&A Expenses | 91.72M | 69.46M | 65.72M | 57.37M | 62.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.12M | 168.69M | 178.28M | 157.21M | 155.97M |
| Operating Income | -178.37M | -166.76M | -111.51M | -155.63M | -139.04M |
| Income Before Tax | -183.03M | -306.18M | -134.37M | -161.38M | -150.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -183.03M | -306.18M | -134.37M | -161.38M | -150.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.03M | -306.18M | -134.37M | -161.38M | -150.02M |
| EBIT | -178.37M | -166.76M | -111.51M | -155.63M | -139.04M |
| EBITDA | -175.51M | -164.08M | -109.22M | -153.33M | -136.66M |
| EPS Basic | -1.52 | -2.55 | -1.12 | -1.36 | -1.27 |
| Normalized Basic EPS | -0.32 | -1.59 | -0.70 | -0.85 | -0.79 |
| EPS Diluted | -1.52 | -2.55 | -1.12 | -1.36 | -1.27 |
| Normalized Diluted EPS | -0.32 | -1.59 | -0.70 | -0.85 | -0.79 |
| Average Basic Shares Outstanding | 120.10M | 119.98M | 119.46M | 118.50M | 118.08M |
| Average Diluted Shares Outstanding | 120.10M | 119.98M | 119.46M | 118.50M | 118.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |